|
Plasmid-based
vaccine for treating atherosclerosis - PEI:
DNA vector formulations for in vitro and in vivo gene delivery -
Gene
encoding a multidrug resistance human P-glycoprotein homologue on
chromosome 7p15-21 and uses thereof - Antigen
constructs useful in the detection and differentiation of antibodies
to HIV - Modified
proteins of the TGF-.beta. superfamily, including morphogenic proteins
- Osteoporosis treatment -
DCR-5 bone affecting
ligand - Antibody
against LAR phosphatase subunit - Crude
extract from Viscum album coloratum, and proteins and lectins isolated
therefrom - Tie-2 ligand-3 - Non-endogenous,
constitutively activated human serotonin receptors and small molecule
modulators thereof - DNA
encoding the human serine protease EOS - Production
of lysosomal enzymes in plants by transient expression - Process
for the production of plants with enhanced growth characteristics
- Transformation
method and transgenic plants produced thereby
Plasmid-based vaccine for treating atherosclerosis
A plasmid-based vaccine is provided herein based on the
combination of DNA segments coding for one or more B cell epitopes
of CETP and one or more broad range helper T cell epitopes.
Administration of the plasmids as a vaccine to a vertebrate
subject provides an immune response to the subject's endogenous
CETP and modulation of CETP activity, leading to prevention or
reversal of various manifestations of heart disease. The vaccines
provide an advantageous strategy for the prevention or treatment
of atherosclerosis.
Thomas, Lawrence J.
Avant Immunotherapeutics, Inc.; January 25, 02005
#6846808
PEI: DNA vector formulations for in vitro and in vivo gene
delivery
The present invention relates generally to the fields of
nucleic acid transfection. More particularly, it concerns novel
polycation:nucleic acid compositions, methods of preparation of
such compositions and methods of transfecting cells with such
compositions.
Cristiano, Richard J.; Yamashita, Motoyuki
Board of Regents, The University of Texas System; January 25, 02005
#6846809
Gene encoding a multidrug resistance human P-glycoprotein
homologue on chromosome 7p15-21 and uses thereof
The invention relates to an MDR family P-glycoprotein located
on human chromosome 7p15-21, polynucleotide sequences encoding
this P-glycoprotein and fragments thereof. This gene is utilized
in methods for assessing cancer cell susceptibility to therapies
directed against multidrug resistance, and for the design of
diagnostic and therapeutic methods relating to cancer multidrug
resistance. The invention also relates to methods for determining
whether a test compound may inhibit multidrug resistance.
Frank, Markus H.; Sayegh, Mohamed H.
The Brigham and Women's Hospital, Inc.; January 25, 02005
#6846883
Antigen constructs useful in the detection and differentiation of
antibodies to HIV
Isolated HIV-1 Group O env polypeptides obtained from the HIV-1
isolate HAM112 are claimed, as well as (a) antigen constructs
comprising fusions of one or more of each of HIV-1 Group O env
polypeptides and HIV-1 Group M env polypeptide and (b) further
antigen constructs containing additional Group O sequences and
especially the gp41 IDR of isolate HAM112. Also claimed are
polynucleotide sequences encoding the above, expression vectors
comprising the same, host cells transformed thereby, and
immunoassay methods and kits utilizing the antigen constructs of
the invention.
Hackett, Jr., John R.; Yamaguchi, Julie; Golden,
Alan M.; Brennan, Catherine A.; Hickman, Robert K.; Devare, Sushil
G.
Abbott Laboratories; January 25, 02005
#6846905
Modified proteins of the TGF-.beta. superfamily, including
morphogenic proteins
The invention provides modified proteins and DNAs of the TGF-.beta.
superfamily including modified morphogenic proteins. The proteins
of the present invention display altered biological or biochemical
attributes. Specifically, the modified proteins are designed
through manipulation or exchange of subdomains among two or more
members of the superfamily such that certain desired attributes
are mixed-and-matched and then exploited therapeutically.
Oppermann, Hermann; Tai, Mei-Sheng; McCartney,
John
Stryker Corporation; January 25, 02005
#6846906
Osteoporosis treatment
There is disclosed a process of treating or alleviating the
symptoms of pathological conditions in which bone density is
decreased, which comprises inhibiting, in a mammalian patient
suffering from such a condition, the formation in vivo of a
tertiary complex of IL-11, its cell surface membrane receptor and
the cell surface glycoprotein gp130. Examples of such substances
are recombinant soluble IL-11 receptor mutants modified, as
compared with native IL-11 receptor, at their gp130 binding site,
and peptides which can interact with IL-11. The process of the
invention not only inhibits bone resorption and hence bone loss,
but also increases the process of bone formation to increase bone
density.
Shaughnessy, Stephen; Austin, Richard Carl
Hamilton Civic Hospitals Research Centre; January 25, 02005
#6846907
DCR-5 bone affecting ligand
DCR5, a protein related to DAN (Differential-screening-selected
gene Aberrative in Neuroblastoma) and related nucleic acids are
provided. Included are natural DCR5 homologs from several species
and proteins comprising a DCR5 domain having specific activity,
particularly the ability to antagonize a bone morphogenetic
protein. The proteins may be produced recombinantly from
transformed host cells with the subject nucleic acids. Also
provided are isolated hybridization probes and primers capable of
specifically hybridizing with the disclosed genes, specific
binding agents and methods of making and using the subject
compositions.
Economides, Aris N.; Stahl, Neil
Regeneron Pharmaceuticals, Inc.; January 25, 02005
#6846908
Antibody against LAR phosphatase subunit
Antibodies to a LAR phosphatase subunit, particularly
antibodies having specificity to an intracellular domain of a
phosphatase subunit, methods for generation thereof and cells
producing these antibodies, and determination and examination
methods of LAR/LAR derived molecules using these antibodies, as
well as uses of these antibodies in diagnosis and therapy of
thyroid cancer are disclosed.
Yamamoto, Hiroshi; Tsujikawa, Kazutake; Uchino,
Yukiko; Konishi, Noboru
Fuso Pharmaceutical Industries, Ltd.; January 25, 02005
#6846912
Crude extract from Viscum album coloratum, and proteins and
lectins isolated therefrom
Disclosed is an extract from Korean mistletoe KM-110, which is
of immunity enhancement and activity against tumor metastasis and
can be used as an adjuvant material for vaccines applicable for
the induction of humoral and cell-mediated immunity. Also
disclosed are its fractions, a protein fraction KM-AS, a lectin
fraction KML-C, lectin components KML-IIU and KML-IIL, which both
are further purified from lectin fraction KML-C, a protein KMHBP
which is obtained through heparin binding chromatography eluting
with NaCl from a fraction C-free AS which is a portion of the
KM-AS free of KML-C, and a mixture KM of the KMHBP and the KML-C.
They are revealed as to their roles in the humoral and
cell-mediated immunity enhancement and antitumoral activity.
Kim, Jongbae; Song, Seongkyu; Suh, Byungsun; Lee,
Kwanhee; Doo, Myoungsool; Kwak, Jinhwan; Song, Byeoungdoo; Yoon,
Taekjoon; Kang, Taebong; Park, Choonho
Mistle Biotech Co., Ltd.; January 25, 02005
#6846913
Tie-2 ligand-3
The present invention provides for an isolated nucleic acid
molecule encoding a member of the TIE ligand family. The present
invention also provides for an isolated nucleic acid molecule
encoding TIE ligand-3 or TIE ligand-4. In addition, the invention
provides for a receptorbody which specifically binds TIE ligand-3
or TIE ligand-4. The invention also provides an antibody which
specifically binds TIE ligand-3 or TIE ligand-4. The invention
further provides for an antagonist of TIE. The invention also
provides for therapeutic compositions as well as a method of
blocking blood vessel growth, a method of promoting
neovascularization, a method of promoting the growth or
differentiation of a cell expressing the TIE receptor, a method of
blocking the growth or differentiation of a cell expressing the
TIE receptor and a method of attenuating or preventing tumor
growth in a human.
Valenzuela, David M.; Jones, Pamela F.;
Yancopoulos, George D.
Regeneron Pharmaceuticals, Inc.; January 25, 02005
#6846914
Non-endogenous, constitutively activated human serotonin
receptors and small molecule modulators thereof
Disclosed herein are non-endogenous, constitutively activated
forms of the human 5-HT.sub.2A and human 5-HT.sub.2C receptors and
uses of such receptors to screen candidate compounds. Further
disclosed herein are candidate compounds identified by the
screening method which act at the 5HT.sub.2A receptors. Yet
further disclosed is a new class of compounds which act at the
5HT.sub.2A receptors.
Behan, Dominic P; Chalmers, Derek T; Liaw, Chen W;
Russo, Joseph F; Thomsen, William J
Arena Pharmaceuticals, Inc.; January 25, 02005
#6846919
DNA encoding the human serine protease EOS
Here we describe the molecular identification of a cDNA
encoding a novel serine protease we have termed protease EOS. The
deduced amino acid sequence, and it alignment with other
well-characterized serine proteases indicates that it is a member
of the S1 serine protease family. We have found that the protease
EOS mRNA is expressed in platelets and leukocytes and more
specifically eosinophils. Although this protease is abundantly
expressed in ovary, retina and stomach, where it may perform
important functions, its expression in platelets and certain cells
of the immune system suggests that it may play roles in thrombosis
and in the immune process. Enzymatically active protease EOS is
amenable to further biochemical analyses for the identification of
physiological substrates and specific modulators.
Darrow, Andrew; Qi, Jenson; Andrade-Gordon,
Patricia
Ortho-McNeil Pharmaceutical, Inc.; January 25, 02005
#6846920
Production of lysosomal enzymes in plants by transient expression
The invention relates to the production of enzymatically active
recombinant human and animal lysosomal enzymes involving
construction and expression of recombinant expression constructs
comprising coding sequences of human or animal lysosomal enzymes
in a plant expression system. The plant expression system provides
for post-translational modification and processing to produce a
recombinant gene product exhibiting enzymatic activity. The
invention is demonstrated by working examples in which transgenic
tobacco plants express recombinant expression constructs
comprising human glucocerebrosidase nucleotide sequences. The
invention is also demonstrated by working examples in which
transfected tobacco plants express recombinant viral expression
constructs comprising human .alpha. galactosidase nucleotide
sequences. The recombinant lysosomal enzymes produced in
accordance with the invention may be used for a variety of
purposes, including but not limited to enzyme replacement therapy
for the therapeutic treatment of human and animal lysosomal
storage diseases.
Erwin, Robert L.; Grill, Laurence K.; Pogue,
Gregory P.; Turpen, Thomas H.; Kumagai, Monto H.
Large Scale Biology Corporation; January 25, 02005
#6846968
Process for the production of plants with enhanced growth
characteristics
The invention is drawn to plant cell transformation with a
nucleic acid construct comprising a prokaryotic ammonium-specific
asparagine synthetase, type A, coding sequence, operably linked to
a chloroplast transit peptide-encoding sequence, wherein said
plant cells also contain a nucleic acid construct comprising a
chloroplastic glutamine synthetase coding sequence in antisense
orientation. Plant cells containing both nucleic acid constructs,
and plants regenerated therefrom, exhibit improved growth
characteristics.
Donn, Gunter; Eckes, Peter; Mullner, Hubert;
Dudits, Denes; Feher, Attila; Paulovics, Katalin
Hoecht Schering AgrEvo GmbH; January 25, 02005
#6846969
Transformation method and transgenic plants produced thereby
This invention relates to methods for producing, at a high
frequency, transgenic plants that contain little if any vector
sequences, have simple integration patterns, contain few copies of
the transgene at each locus, express the transgene at all stages
of development and do not exhibit transgene silencing. The method
comprises introducing minimal transgene expression cassettes,
which are substantially or totally devoid of vector sequences, by
direct DNA transfer, preferably by particle or microprojectile
bombardment. This invention also relates to transformed plant
cells, the transgenic plants regenerated therefrom, and subparts
of the transgenic plants produced by the methods of this
invention. The invention also includes all progeny and subsequent
progeny (i.e., all subsequent generations) derived from primary
transformants through selfing or crossing.
Christou, Paul; Kohli, Ajay
Plant Bioscience Limited; January 25, 02005
#6846970
Patent Alert
|
